WO2008144728A1 - Conjugués qui se lient à une protéine sanguine telle que la sérum albumine humaine et des procédés les utilisant dans des applications diagnostiques et thérapeutiques - Google Patents

Conjugués qui se lient à une protéine sanguine telle que la sérum albumine humaine et des procédés les utilisant dans des applications diagnostiques et thérapeutiques Download PDF

Info

Publication number
WO2008144728A1
WO2008144728A1 PCT/US2008/064359 US2008064359W WO2008144728A1 WO 2008144728 A1 WO2008144728 A1 WO 2008144728A1 US 2008064359 W US2008064359 W US 2008064359W WO 2008144728 A1 WO2008144728 A1 WO 2008144728A1
Authority
WO
WIPO (PCT)
Prior art keywords
meg
do3a
composition
imaging
compound
Prior art date
Application number
PCT/US2008/064359
Other languages
English (en)
Inventor
Edmund R. Marinelli
Natarajan Raju
Radhakrishna K. Pillai
Michael F. Tweedle
Kondareddiar Ramalingam
Original Assignee
Bracco Imaging S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging S.P.A. filed Critical Bracco Imaging S.P.A.
Publication of WO2008144728A1 publication Critical patent/WO2008144728A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

De nouvelles constructions et de nouveaux agents utiles pour des applications diagnostiques et thérapeutiques ont été développés. Les constructions comprennent un chélateur, un premier lieur et soit un acide aminé hydrophobe soit un 'hydrophobe' (un acide non aminé hydrophobe), éventuellement liés à un second lieur et un vecteur de ciblage. La structure de tels composés permet d'obtenir un temps prolongé de résidence dans le sang, et augmente ainsi leur utilité dans l'imagerie et le traitement de la maladie. La présente invention concerne en outre des composés qui fournissent une fraction élevée liée au sérum et/ou des composés qui ont une relaxivité mesurée élevée dans le Seronorm™.
PCT/US2008/064359 2007-05-21 2008-05-21 Conjugués qui se lient à une protéine sanguine telle que la sérum albumine humaine et des procédés les utilisant dans des applications diagnostiques et thérapeutiques WO2008144728A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93109007P 2007-05-21 2007-05-21
US60/931,090 2007-05-21

Publications (1)

Publication Number Publication Date
WO2008144728A1 true WO2008144728A1 (fr) 2008-11-27

Family

ID=40122211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064359 WO2008144728A1 (fr) 2007-05-21 2008-05-21 Conjugués qui se lient à une protéine sanguine telle que la sérum albumine humaine et des procédés les utilisant dans des applications diagnostiques et thérapeutiques

Country Status (1)

Country Link
WO (1) WO2008144728A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072607A (zh) * 2013-03-29 2014-10-01 中国科学院化学研究所 一种有机金属钌缀合蛋白及其制备方法与应用
WO2016083605A1 (fr) * 2014-11-28 2016-06-02 Ge Healthcare As Formulations complexes de lanthanide
JP2017538685A (ja) * 2014-11-28 2017-12-28 ジーイー・ヘルスケア・アクスイェ・セルスカプ 金属錯体製剤
CN108288072A (zh) * 2018-01-26 2018-07-17 深圳市唯特视科技有限公司 一种基于生成对抗网络的面部表情合成方法
WO2018200615A3 (fr) * 2017-04-27 2019-01-10 The Regents Of The University Of California Produits de contraste pour irm modifiés et leurs utilisation
CN110426464A (zh) * 2019-07-08 2019-11-08 苏州天马药业有限公司 一种葡甲胺中异构体的hplc检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241018A1 (en) * 2003-01-13 2006-10-26 De Haen Christoph Linkers for radiopharmaceutical compounds
US20060269479A1 (en) * 2005-04-19 2006-11-30 Colton Clark K Amphiphilic polymers and methods of use thereof
US20070003479A1 (en) * 1995-02-01 2007-01-04 Epix Pharmaceuticals, Inc., A Delaware Corporation Diagnostic imaging contrast agents with extended blood retention

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003479A1 (en) * 1995-02-01 2007-01-04 Epix Pharmaceuticals, Inc., A Delaware Corporation Diagnostic imaging contrast agents with extended blood retention
US20060241018A1 (en) * 2003-01-13 2006-10-26 De Haen Christoph Linkers for radiopharmaceutical compounds
US20060269479A1 (en) * 2005-04-19 2006-11-30 Colton Clark K Amphiphilic polymers and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COMBLIN ET AL.: "Designing New MRI Contrast Agents: a Coordination Chemistry Challenge", COORDINATION CHEMISTRY REVIEWS, vol. 185-186, October 1999 (1999-10-01), pages 451 - 470 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072607A (zh) * 2013-03-29 2014-10-01 中国科学院化学研究所 一种有机金属钌缀合蛋白及其制备方法与应用
CN104072607B (zh) * 2013-03-29 2019-01-15 中国科学院化学研究所 一种有机金属钌缀合蛋白及其制备方法与应用
WO2016083605A1 (fr) * 2014-11-28 2016-06-02 Ge Healthcare As Formulations complexes de lanthanide
CN107001293A (zh) * 2014-11-28 2017-08-01 通用电气医疗集团股份有限公司 镧系元素络合物制剂
JP2017535553A (ja) * 2014-11-28 2017-11-30 ジーイー・ヘルスケア・アクスイェ・セルスカプ ランタニド錯体製剤
JP2017538685A (ja) * 2014-11-28 2017-12-28 ジーイー・ヘルスケア・アクスイェ・セルスカプ 金属錯体製剤
CN107001293B (zh) * 2014-11-28 2023-09-19 通用电气医疗集团股份有限公司 镧系元素络合物制剂
US11400172B2 (en) 2014-11-28 2022-08-02 Ge Healthcare As Lanthanide complex formulations
US11186553B2 (en) 2014-11-28 2021-11-30 Ge Healthcare As Metal complex formulations
RU2707070C2 (ru) * 2014-11-28 2019-11-22 ДжиИ Хелткер АС Композиции, содержащие комплексы металлов ряда лантаноидов
US10576169B2 (en) 2014-11-28 2020-03-03 Ge Healthcare As Lanthanide complex formulations
AU2015352426B2 (en) * 2014-11-28 2020-03-05 Ge Healthcare As Lanthanide complex formulations
JP2020517584A (ja) * 2017-04-27 2020-06-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 修飾ｍｒｉ造影剤およびその使用
WO2018200615A3 (fr) * 2017-04-27 2019-01-10 The Regents Of The University Of California Produits de contraste pour irm modifiés et leurs utilisation
CN108288072A (zh) * 2018-01-26 2018-07-17 深圳市唯特视科技有限公司 一种基于生成对抗网络的面部表情合成方法
CN110426464A (zh) * 2019-07-08 2019-11-08 苏州天马药业有限公司 一种葡甲胺中异构体的hplc检测方法

Similar Documents

Publication Publication Date Title
AU2003299957B2 (en) Improved gastrin releasing peptide compounds
EP2790732B1 (fr) Analogues conjugués de somatostatine coupés pour des applications biologiques
EP2097438B1 (fr) Conjugues peptidiques se liant a la fibrine pour des applications de diagnostic et therapeutiques
JP5676673B2 (ja) 癌の画像化および処置
US7922998B2 (en) Gastrin releasing peptide compounds
US20110280802A1 (en) Linkers For Radiopharmaceutical Compounds
US20120009122A1 (en) Gastrin releasing peptide compounds
US8420050B2 (en) Gastrin releasing peptide compounds
WO2008144728A1 (fr) Conjugués qui se lient à une protéine sanguine telle que la sérum albumine humaine et des procédés les utilisant dans des applications diagnostiques et thérapeutiques
JP4264263B2 (ja) コレシストキニンアゴニストおよびアンタゴニストの調製ならびにそれらの治療および診断の使用
WO2022098745A1 (fr) Compositions, systèmes d'administration et méthodes utiles dans la thérapie antitumorale
US7611692B2 (en) Gastrin releasing peptide compounds
WO2023229458A1 (fr) Agonistes de sstr2 marqués par un radioisotope avec des lieurs
US20060239923A1 (en) Gastrin releasing peptide compounds
WO2005067983A1 (fr) Composés peptidiques de libération de gastrine améliorés
MXPA06007322A (en) Improved gastrin releasing peptide compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08756047

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08756047

Country of ref document: EP

Kind code of ref document: A1